AU2010311186B2 - Therapeutic peptides - Google Patents

Therapeutic peptides Download PDF

Info

Publication number
AU2010311186B2
AU2010311186B2 AU2010311186A AU2010311186A AU2010311186B2 AU 2010311186 B2 AU2010311186 B2 AU 2010311186B2 AU 2010311186 A AU2010311186 A AU 2010311186A AU 2010311186 A AU2010311186 A AU 2010311186A AU 2010311186 B2 AU2010311186 B2 AU 2010311186B2
Authority
AU
Australia
Prior art keywords
amino acid
groups
group
peptide
substituting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010311186A
Other languages
English (en)
Other versions
AU2010311186A1 (en
Inventor
Terkel Hansen
Martina Havelkova
Morten Strom
Veronika Torfoss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lytix Biopharma AS
Original Assignee
Lytix Biopharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lytix Biopharma AS filed Critical Lytix Biopharma AS
Publication of AU2010311186A1 publication Critical patent/AU2010311186A1/en
Application granted granted Critical
Publication of AU2010311186B2 publication Critical patent/AU2010311186B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2010311186A 2009-11-02 2010-11-02 Therapeutic peptides Active AU2010311186B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0919194.1A GB0919194D0 (en) 2009-11-02 2009-11-02 Compounds
GB0919194.1 2009-11-02
PCT/GB2010/002024 WO2011051692A1 (en) 2009-11-02 2010-11-02 Therapeutic peptides

Publications (2)

Publication Number Publication Date
AU2010311186A1 AU2010311186A1 (en) 2012-05-31
AU2010311186B2 true AU2010311186B2 (en) 2015-09-24

Family

ID=41435032

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010311186A Active AU2010311186B2 (en) 2009-11-02 2010-11-02 Therapeutic peptides

Country Status (14)

Country Link
US (1) US8809280B2 (enExample)
EP (1) EP2496596B1 (enExample)
JP (1) JP5810090B2 (enExample)
KR (1) KR101730680B1 (enExample)
CN (1) CN102762586B (enExample)
AU (1) AU2010311186B2 (enExample)
CA (1) CA2777749C (enExample)
DK (1) DK2496596T3 (enExample)
ES (1) ES2621188T3 (enExample)
GB (1) GB0919194D0 (enExample)
NZ (1) NZ599791A (enExample)
PL (1) PL2496596T3 (enExample)
RU (2) RU2548905C2 (enExample)
WO (1) WO2011051692A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI852183B (zh) 2011-12-28 2024-08-11 日商中外製藥股份有限公司 胜肽化合物之環化方法
US10815489B2 (en) 2015-03-13 2020-10-27 Chugai Seiyaku Kabushiki Kaisha Modified aminoacyl-tRNA synthetase and use thereof
GB201601868D0 (en) 2016-02-02 2016-03-16 Lytix Biopharma As Methods
KR20180133463A (ko) * 2016-04-14 2018-12-14 타오 헬스 라이프 파마 가부시키가이샤 아밀로스페로이드(aspd) 결합 저해 펩타이드, 및 평가 및 스크리닝 방법
US12391971B2 (en) 2017-01-31 2025-08-19 Chugai Seiyaku Kabushiki Kaisha Method for synthesizing peptides in cell-free translation system
GB201705255D0 (en) 2017-03-31 2017-05-17 Univ I Tromsø - Norges Arktiske Univ Bioactive cyclic compounds
WO2018188761A1 (en) 2017-04-13 2018-10-18 Lytix Biopharma As Method of reducing population size of tregs and/or mdscs
EP3636656A4 (en) 2017-06-09 2021-04-14 Chugai Seiyaku Kabushiki Kaisha METHOD OF SYNTHESIS OF PEPTIDE WITH N-SUBSTITUTED AMINO ACID
CN111479819B (zh) 2017-12-15 2024-06-14 中外制药株式会社 制备肽的方法和处理碱的方法
US12312297B2 (en) 2018-11-07 2025-05-27 Chugai Seiyaku Kabushiki Kaisha O-substituted serine derivative production method
CN119143631A (zh) 2018-11-30 2024-12-17 中外制药株式会社 用于肽化合物或酰胺化合物的脱保护方法和在固相反应中的树脂脱除方法以及用于生产肽化合物的方法
KR102994657B1 (ko) 2019-03-15 2026-07-22 추가이 세이야쿠 가부시키가이샤 방향족 아미노산 유도체의 제조 방법
CN110294793B (zh) * 2019-06-24 2023-10-27 合肥科生景肽生物科技有限公司 Sumo荧光探针及其制备方法
EP4043478A4 (en) 2019-11-07 2024-01-03 Chugai Seiyaku Kabushiki Kaisha CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITING ACTION
CN114790151B (zh) * 2022-02-14 2023-03-31 湖南省湘中制药有限公司 一种2-氰基-2-丙戊酸甲酯的复合催化制备方法
AU2023413685A1 (en) 2022-12-20 2025-06-19 Lytix Biopharma As Compositions comprising an oncolytic peptide and chitosan

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007237431A1 (en) * 2006-04-13 2007-10-25 Aicuris Gmbh & Co. Kg Lysobactin amides
EP2105433A1 (en) * 2008-03-18 2009-09-30 Technische Universität Dresden Modular scaffold for the design of specific molecules for the use as peptidomimetics and inhibitors of protein interaction

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342705A (en) 1979-11-23 1982-08-03 Monsanto Company Methylene thioethers
GR79206B (enExample) 1982-06-03 1984-10-22 Montedison Spa
IT1161927B (it) 1983-03-31 1987-03-18 Montedison Spa Furano-derivati ad attivita' fungicida
DK523288A (da) 1987-10-06 1989-04-07 Hoffmann La Roche Aminosyrederivater
CA1328333C (en) 1988-03-04 1994-04-05 Quirico Branca Amino acid derivatives
US5593967A (en) 1990-08-31 1997-01-14 Warner-Lambert Company Cholecystokinin antagonists, their preparation and therapeutic use
CA2088195A1 (en) 1990-08-31 1992-03-01 David C. Horwell Cholecystokinin antagonists, their preparation and therapeutic use
US5387671A (en) * 1990-12-27 1995-02-07 Abbott Laboratories Hexa- and heptapeptide anaphylatoxin-receptor ligands
US5885782A (en) 1994-09-13 1999-03-23 Nce Pharmaceuticals, Inc. Synthetic antibiotics
IL125163A0 (en) 1996-01-02 1999-01-26 Rhone Poulenc Rorer Pharma Substituted n-[(aminoiminomethyl or aminomethyl) phenyl] propyl amides
US6080767A (en) 1996-01-02 2000-06-27 Aventis Pharmaceuticals Products Inc. Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
US6323227B1 (en) 1996-01-02 2001-11-27 Aventis Pharmaceuticals Products Inc. Substituted N-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
JP3734907B2 (ja) 1996-12-19 2006-01-11 富士写真フイルム株式会社 現像処理方法
EP2078529B1 (en) * 2006-07-10 2014-12-10 PBA3 Biomed GmbH Antimicrobial peptides
GB0724951D0 (en) * 2007-12-20 2008-01-30 Lytix Biopharma As Compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007237431A1 (en) * 2006-04-13 2007-10-25 Aicuris Gmbh & Co. Kg Lysobactin amides
EP2105433A1 (en) * 2008-03-18 2009-09-30 Technische Universität Dresden Modular scaffold for the design of specific molecules for the use as peptidomimetics and inhibitors of protein interaction

Also Published As

Publication number Publication date
BR112012010333A2 (pt) 2016-03-29
WO2011051692A1 (en) 2011-05-05
ES2621188T3 (es) 2017-07-03
KR20120104986A (ko) 2012-09-24
KR101730680B1 (ko) 2017-04-26
RU2676713C2 (ru) 2019-01-10
CN102762586A (zh) 2012-10-31
RU2015111706A (ru) 2015-11-10
PL2496596T3 (pl) 2017-08-31
CN102762586B (zh) 2016-10-05
EP2496596A1 (en) 2012-09-12
JP2013509389A (ja) 2013-03-14
EP2496596B1 (en) 2017-01-11
NZ599791A (en) 2014-10-31
US20130035296A1 (en) 2013-02-07
RU2015111706A3 (enExample) 2018-10-29
DK2496596T3 (en) 2017-04-03
CA2777749C (en) 2019-08-06
US8809280B2 (en) 2014-08-19
RU2012121264A (ru) 2013-12-10
AU2010311186A1 (en) 2012-05-31
GB0919194D0 (en) 2009-12-16
RU2548905C2 (ru) 2015-04-20
JP5810090B2 (ja) 2015-11-11
CA2777749A1 (en) 2011-05-05

Similar Documents

Publication Publication Date Title
CA2777749C (en) Therapeutic peptides comprising a disubstituted beta-amino acid for treating microbial infections or tumours
CN106852146B (zh) 细胞穿透肽及其制备和使用方法
EP1263471B1 (en) Antimicrobial compounds and formulations
US8354374B2 (en) Peptides having pharmacological activity for treating disorders associated with altered cell migration, such as cancer
SK286581B6 (sk) Deriváty dolastatinu 15, farmaceutický prípravok s ich obsahom a ich použitie
TW201004647A (en) Novel dual targeting antitumoural conjugates
CN102037005B (zh) 改善治疗功效的新光学纯化合物
EP3700548A1 (en) Polypeptide conjugates for intracellular delivery of stapled peptides
JPH06506699A (ja) 抗血栓性ペプチドおよび偽ペプチド
CA2883531A1 (en) Stable peptide-based furin inhibitors
US7919468B2 (en) Compounds useful as modulators of the proteasome activity
JP5433586B2 (ja) ペプチド修飾の方法
CN113896766A (zh) 一种新的抗肿瘤环肽类活性分子、制备方法及应用
BR112012010333B1 (pt) Peptídeo ou derivado de aminoácido, seu uso, bem como formulação que os compreendem
JPWO2012118124A1 (ja) 新規ケモカイン受容体拮抗剤
KR20250122523A (ko) 종양 용해성 펩티드 및 키토산을 포함하는 조성물
WO2025080942A1 (en) Proteasome inhibitors and methods of use thereof
WO2012124641A1 (ja) 抗癌剤の活性増強剤
AU2021408143A1 (en) Cyclic peptides and uses thereof
JPH07242563A (ja) ガン転移抑制剤

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)